申请人:Rhone-Poulenc Rorer S.A.
公开号:US05902803A1
公开(公告)日:1999-05-11
Compounds of formula (I), wherein R is a hydrogen atom or a carboxy, alkoxycarbonyl, --CO--NR.sub.4 R.sub.5, --PO.sub.3 H.sub.2 or --CH.sub.2 OH radical, and R.sub.1 is an -alk-NH.sub.2, -alk-NH--CO--R.sub.3, -alk-COOR.sub.4, -alk-CO--NR.sub.5 R.sub.6 or --CO--NH--R.sub.7 radical. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartame (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.
式(I)化合物,其中R为氢原子或羧基、烷氧羰基、--CO--NR₄R₅、--PO₃H₂或--CH₂OH基团,R₁为-烷基-NH₂、-烷基-NH--CO--R₃、-烷基-COOR₄、-烷基-CO--NR₅R₆或--CO--NH--R₇基团。式(I)化合物具有宝贵的药理特性,是α-氨基-3-羟基-5-甲基-4-异噁唑丙酸(AMPA)受体即quisqualate受体的拮抗剂。此外,式(I)化合物是非竞争性N-甲基-D-天冬氨酸(NMDA)受体的拮抗剂,更具体地说是NMDA受体甘氨酸调节位点的配体。